<DOC>
	<DOCNO>NCT02281552</DOCNO>
	<brief_summary>This 12 week study evaluate efficacy safety 11 mg tofacitinib modify release tablet take day patient rheumatoid arthritis continue take methotrexate . Results modify release tablet compare efficacy safety 5 mg tofacitinib immediate release tablet take twice day patient rheumatoid arthritis continue take methotrexate .</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>diagnosis rheumatoid arthritis currently take stable dose methotrexate evidence active latent inadequately treat tuberculosis evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic allergic disease clinically significant infection within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Tofacitinib , CP-690,550 , Janis kinase , JAK inhibitor , modify release , Xeljanz</keyword>
</DOC>